UK investment fund Silchester International Investors increased its stake in Santen Pharmaceutical, raising its holding to 10.25%. The amended large-shareholding report was reportedly filed with the Kanto Local Finance Bureau on the 26th.
An amended large-shareholding report filed with the Kanto Local Finance Bureau on the 26th by UK-based investment fund Silchester International Investors showed that its holding in Santen Pharmaceutical had reached 10.25% as of the 23rd. This was up from 9.23% in the previous report.
The stated purpose of the holding is to propose changes to capital policy, improvements in capital efficiency, a review of the business structure and stronger corporate governance. Specific measures cited include increasing dividends, share buybacks and the cancellation of treasury shares.
Santen Pharmaceutical has not commented on the additional purchases.